KI-67 As a Predictive Indicator of Papillary Thyroid Cancer in Iraqi Patients

Overview

Journal Probl Endokrinol (Mosk)

Date 2025 Jan 27

PMID 39868448

Authors

Noor Mohammed Al-Timimi

Abed Hassan Baraaj

Affiliations

Soon will be listed here.

Abstract

Background: KI-67 (MKI-67 in humans) is a protein able to bind to DNA which contributes to cell growth and cell proliferation. KI-67 is currently considered as a biomarker that is widely utilized as prognostic indicator for evaluating cell proliferation, diagnosing diseases, and conducting research. Several different kinds of cancer have high Ki-67 expression, which simplifying the choice of treatment for individuals with various cancer types.

Aim: The objective was to evaluate the expression of KI67 in patients suffering papillary thyroid cancer (PTC) also the association between patients age and gender and KI67 expression.

Materials And Methods: To undertake an in-depth investigation of KI67 in malignant and normal tissues, we used thyroid tissue sections to analyze KI67 expression in 70 samples, 50 different PTC (44 female and 6 male), and 20 normal types (10 for each gender). Each group's average age is between 20 and 60.

Results: The analysis of the data revealed a substantial difference in the expression of ki67 between the patients and control groups. Ki67 expression and either gender or age did not significantly correlate.

Conclusion: This study suggest that KI67 may be a crucial marker for assessing the aggressiveness of tumors and inflammatory diseases.

References

Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C . Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biol. 2005; 26(1):50-6. DOI: 10.1159/000084340. View

Dwivedi S, Khandeparkar S, Joshi A, Kulkarni M, Bhayekar P, Jadhav A . Study of Immunohistochemical Markers (CK-19, CD-56, Ki-67, p53) in Differentiating Benign and Malignant Solitary Thyroid Nodules with special Reference to Papillary Thyroid Carcinomas. J Clin Diagn Res. 2017; 10(12):EC14-EC19. PMC: 5296437. DOI: 10.7860/JCDR/2016/22428.9114. View

Davey M, Hynes S, Kerin M, Miller N, Lowery A . Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel). 2021; 13(17). PMC: 8430879. DOI: 10.3390/cancers13174455. View

Pan D, Wen D, Luo Y, Chen G, Yang H, Chen J . The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases. Onco Targets Ther. 2017; 10:3261-3276. PMC: 5505609. DOI: 10.2147/OTT.S135593. View

Maia R, Dos Santos G, Reis S, Viana N, Pimenta R, Guimaraes V . Can we use Ki67 expression to predict prostate cancer aggressiveness?. Rev Col Bras Cir. 2022; 49:e20223200. PMC: 10578861. DOI: 10.1590/0100-6991e-20223200-en. View

Lei Y, Zhao X, Feng Y, He D, Hu D, Min Y . The Value of Ki-67 Labeling Index in Central Lymph Node Metastasis and Survival of Papillary Thyroid Carcinoma: Evidence From the Clinical and Molecular Analyses. Cancer Control. 2023; 30:10732748231155701. PMC: 9905023. DOI: 10.1177/10732748231155701. View

Ahmed S, Rashed H, Hegazy A, Mohamed A, Elmesallamy W . Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas. Turk Patoloji Derg. 2016; 32(2):70-81. DOI: 10.5146/tjpath.2015.01344. View

Zhou Y, Jiang H, Lu N, Lu B, Chen Z . Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. Asian Pac J Cancer Prev. 2015; 16(4):1605-8. DOI: 10.7314/apjcp.2015.16.4.1605. View

Mao J, Zhang Q, Zhang H, Zheng K, Wang R, Wang G . Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020; 11:265. PMC: 7242632. DOI: 10.3389/fendo.2020.00265. View

10.

Li L, Jiang G, Chen Q, Zheng J . Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2014; 11(3):1566-72. DOI: 10.3892/mmr.2014.2914. View

11.

Lindfors H, Karlsen M, Karlton E, Zedenius J, Larsson C, Ihre Lundgren C . Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer. Sci Rep. 2023; 13(1):1070. PMC: 9852547. DOI: 10.1038/s41598-023-27684-3. View

12.

Sun X, Kaufman P . Ki-67: more than a proliferation marker. Chromosoma. 2018; 127(2):175-186. PMC: 5945335. DOI: 10.1007/s00412-018-0659-8. View

13.

Doubi A, Al-Qannass A, Al-Angari S, Al-Qahtani K, Alessa M, Al-Dhahri S . Trends in thyroid carcinoma among thyroidectomy patients: a 12-year multicenter study. Ann Saudi Med. 2019; 39(5):345-349. PMC: 6832316. DOI: 10.5144/0256-4947.2019.345. View

14.

Remnant L, Kochanova N, Reid C, Cisneros-Soberanis F, Earnshaw W . The intrinsically disorderly story of Ki-67. Open Biol. 2021; 11(8):210120. PMC: 8354752. DOI: 10.1098/rsob.210120. View

15.

Yu L, Hong H, Han J, Leng S, Zhang H, Yan X . Comparison of Survival and Risk Factors of Differentiated Thyroid Cancer in the Geriatric Population. Front Oncol. 2020; 10:42. PMC: 7008846. DOI: 10.3389/fonc.2020.00042. View